BlackRock’s Vivos Therapeutics VVOS Stock Holding History

BlackRock’s Portfolio VVOS Stock Details VVOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12.6K	Hold	27,817	–	–	﹤0.01%	5413
2026 Q1	$32.8K	Hold	27,817	–	–	﹤0.01%	5213
2025 Q4	$56.5K	Hold	27,817	–	–	﹤0.01%	5024
2025 Q3	$86.2K	Buy	+27,817	New	+$126K	﹤0.01%	4865
2024 Q1	–	Sell	-42	Closed	-$522	–	5405
2023 Q4	$522	Buy	42 +1	+2%	+$9	﹤0.01%	5287
2023 Q3	$199	Sell	41 -52	-56%	-$393	﹤0.01%	5381
2023 Q2	$1.19K	Sell	93 -1,853	-95%	-$18.1K	﹤0.01%	5394
2023 Q1	$16.6K	Buy	1,946 +62	+3%	+$1.36K	﹤0.01%	5275
2022 Q4	$18.9K	Buy	1,884 +41	+2%	+$600	﹤0.01%	5385
2022 Q3	$30K	Sell	1,843 -52	-3%	-$1.58K	﹤0.01%	5452
2022 Q2	$60K	Sell	1,895 -30	-2%	-$1.25K	﹤0.01%	5376
2022 Q1	$129K	Sell	1,925 -93	-5%	-$6.08K	﹤0.01%	5229
2021 Q4	$114K	Buy	2,018 +62	+3%	+$4.99K	﹤0.01%	5232
2021 Q3	$198K	Buy	1,956 +1,406	+256%	+$148K	﹤0.01%	4993
2021 Q2	$68K	Buy	550 +88	+19%	+$14.3K	﹤0.01%	5138
2021 Q1	$77K	Buy	+462	New	+$82.5K	﹤0.01%	4867

Other funds holding VVOS

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

IWM

IHT Wealth Management Chicago, Illinois $4.7B AUM 25.67% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

BRWA

B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

CWM

Centurion Wealth Management Mclean, Virginia $418M AUM 23.14% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SFA

Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

BlackRock's VVOS Position: Q2 2026 in Review

BlackRock held its Vivos Therapeutics (VVOS) position steady in Q2 2026 at 27,817 shares worth $12.6K. The position accounts for ﹤0.01% of the portfolio, ranked #5413.

BlackRock first reported a position in VVOS in Q1 2021 and has held it in 16 quarters since. The position peaked at $198K in Q3 2021. 23 funds tracked by Wall St. Rank hold VVOS as of Q2 2026.

BlackRock held 27,817 shares of Vivos Therapeutics worth $12.6K as of Q2 2026.
BlackRock left its Vivos Therapeutics share count unchanged in Q2 2026.
Vivos Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #5413 holding.
BlackRock first reported a position in Vivos Therapeutics in Q1 2021 and has held it in 16 quarters since.
BlackRock's Vivos Therapeutics position peaked at $198K in Q3 2021.
23 funds tracked by Wall St. Rank held Vivos Therapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.